Improving the asthma arsenal. by Reuther, C G
Ithma
Singh, a professor in the Department of
Materials Science and Engineering at the
University ofFlorida inGainesvile; Guenther
Hochhaus and James Talton, an associate
professor and postdoctoral associate, respec-
tively, in the university's Department of
Pharmaceutics; and James Fitz-Gerald of the
Naval Research Laboratory in Washington,
DC, have begun using the new technique-
pulse laser deposition- to coat glucocorticoids
with thin layers ofa biodegradable polymer.
Glucocorticoids are the strongest and
longest-lasting asthma treatment in use today.
They are Lised to reduce inflammation in the
lungs of mnaniy asthnma patients, but once the
drugs are absorbed into the bloodstream, they
becomiie ineffective. Recent studies have also
suggested that high concentrations of gluco-
corticoids in the blood may inhibit growth in
children by obstructing the body's normnal
hormone productioni. The hope is that coat-
ing these inhaled steroids will reduce the con-
cenitrationis that collect in the blood ofasthma
patiernts.
iseaisc faSt
of a pols-
0met;. to the ~tes~41 essentiallydoesn't
change the size ofthe inhaled partile," says
Talton. Becaus the g-oating known as poly
(lactic-co-glycolic) acid (PLGA) dissolves
slowly, it provides longer sustained release of
the drug, says Talton. Keeping the steroid in
the lungs longer means less is absorbed sys-
temically, and this means fewer side effects.
The method is especially appealing
because it gives researchers great flexibility in
selecting what particles they use and the prop-
erties ofthe coatings they apply. "Most ofthe
coating techniques that have been arotunid.
especially in the pharmaceutical area are
very specific to the type of material you
use," explains Singh. 'The nice thing about
this process is it s more universal. You can
take alimost any particle, A, and allmost any
coating, B, and put a coating of B on A....
YouL can even dial in the thickncss ofthe coat-
ing that you need."
Tlhe method is still in its infancv, and
years of stLidy and testing will be necessary
before the drug coating technique canl be used
in asthmiia inhalers. "This has the potcnti.l1 to
he a vets exciting advance in aerosol asthlmla
imiedicationi,' says Dav,id Pedcn. cdirector of
Pulsing Particles
The basic pulse laser techniique was developed
by Singh and Fitz-Cerald at the Enlgineering
Research Center fior Particle Science and
Technology at the University of Florida, a
laboratory established by the National Science
Foundation. "We were looking for a new
coating technique to coat any material poly-
meric materials, ceramics, or metals onto
particles," says Singh.
The method thev arrived at employs a
high-intensity laser to heat the coating sib-
stance, producing a supersonic shock svave of
the heated material called a( plulme. The
plume is produced inside a vacUIlu clhaimiber
containing particles of the substanice to be
coated. "We shoot a laser into that chamber
to create a flux [or flow] ofthe coating materi-
al," says Singh. "The coating mlaterial is then
ready to condense on any surfalce it [contacts],
so it condenses on the drLig particles or what-
ever particles are in the chaimber." Recently,
the technique was used bv a teamii led by Fitz-
Gerald to appls' 20-3()0-1alonanoeter coatiligs of
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silver and rare earth metals to particles ofalu-
mina and silica. The results of that work
appeared in the Journal ofMaterials Research
inAugust 1999.
Research on the use ofpulse laser deposi-
tion for asthma drugs has yet to be published,
but initial data presented at the Fall 1998
meeting of the Materials Research Society
suggested that rats retain coated glucocorti-
coids in their lungs much longer than uncoat-
ed glucocorticoids. The half-life ofthe coated
drugs in the lungs was found to be about one
hour, compared to just over a minute for the
uncoated drugs. That suggests that concentra-
tions in the blood would be lower with the
coated drug, which would reduce the risk of
adverse side effects. And, says Singh, because
the polymer coating is very thin-often less
than 0.1% of the whole coated particle-
there is very little concern that adverse effects
from accumulation of the polymer in the
lungswould be seen.
As an added benefit, the drug's longer
retention time and slower release rate in the
lungs mean that it could probably be used less
frequently. "With this system you can basical-
ly tailor whatever release rate you want, for an
hour or two up to a couple of days," says
Talton. "Any time you have to use a drug less
often," says Peden, "the chances are higher
that people will continue using it [on the cor-
rectschedule]."
ImprovedInhalers
Glucocorticoids are delivered to patients
through inhalers to maximize the action of
the drug on inflamed cells in the lungs,
though the steroids are also sometimes given
orally to patients with severe asthma. "If
they're given [orally] or at really high doses
through inhalation, enough may get into the
bloodstream to inhibit the adrenal gland from
producing endogenous steroids," says Darryl
Zeldin, head of the Clinical Studies Section
ofthe Laboratory ofPulmonary Pathobiology
at the NIEHS. "The body sees the exogenous
steroids and it thinks it doesn't need to pro-
duce endogenous ones that are important for
a numberofbiological processes." Inchildren,
when the production of some steroids slows,
growth may notproceed at the normal rate.
There are also other potential side effects
ofglucocorticoids that are a concern in both
adults and children, says Peden. The drugs
have been associated with changes in the eye,
including cataracts, and they can suppress the
immune system. However, says Zeldin, "The
systemic side effects of inhaled steroids
shouldn't be overstated. . . In most cases,
theyarereallyamazinglysafedrugs."
Still, concern over growth-related side
effects of inhaled corticosteroids (ofwhich
glucocorticoids are a subset) led the Food and
Prug Administration to convene an expert
panel in July 1998 to discuss their continued
use in children, who account for about one-
third ofall asthma patients. The conclusion of
that panel was that not enough evidence of
developmental problems in children exists to
warrant any reduction in the use ofthe drugs.
However, the panel said that such side effects
need to be studied further, and it recom-
mended that physicians monitor the growth
of all children to whom they prescribe the
inhaled steroids.
Recogri;zing subtle abnormalities in the
growth of ildren is difficult, though, and
Peden says asthma itself may cause slight
changes in growth rate, making such effects
even more difficult to identify. Therefore, it
maybe along time before scientists are able to
accurately describe the risks associated with
these asthma treatments.
The debate over the safety of cortico-
steroids has not gone unnoticed by the par-
ents ofsome asthmatic children. "They often
just don't like the notion of their children
being on steroids in the first place," says
Peden, "and whether they are really aware of
the effects on growth or have just heard the
general buzz . .. they may be more reluctant
to give these treatments to their children."
That can be dangerous because severe asthma
attacks can be fatal. Also, other asthma drugs
are generally not as effective as glucocorticoids
at treatingthedisease.
"Ifyou could reduce the systemic absorp-
tion ofthese drugs-at any level-that would
be good," Peden says. Furthermore, he says,
convincing users that the risk ofsuch absorp-
tion has been eliminated would assuage some
oftheir reluctance to use glucocorticoid asth-
ma inhalers. That would likely result in less
morbiditydue to asthma, Peden says.
In the meantime, many other new drugs
are being developed that attack asthma
inflammation in other ways and avoid some
ofthe potential risks associated with steroids.
But thus far nothing as effective as glucocorti-
coids is available. "Steroids are certainly the
mainstay of asthma therapy right now,"
Zeldin says, "and they will probably continue
to be amainstay in the future."
If the Florida researchers are correct, it
may be possible to make steroids safer, there-
by eliminating at least some of the need for
new drugs. While Hochhaus concedes that
the coating technique would add to the pro-
duction costs ofglucocorticoid drugs, he says,
"It would probably not increase it too much.
Compared to developing a new drug-a new
chemical entity-it wouldn't be more expen-
sive than that." Keeping costs low could be
especially important when producing asthma
therapies because the ailment is known to dis-
proportionatelyaffect the poor.
OngoingResearch
There is some reason to think that the PLGA
coating will not be a panacea for all the prob-
lems with glucocorticoid asthma drugs. Peden
points out that often a large portion of the
inhaled asthma drug that enters the blood-
stream does so not through the lungs but
through the gastrointestinal tract: "Sometimes
the majority of what comes out of the
metered-dose inhaler is swallowed rather than
inhaled," he says. There is little at this point
to suggest that the new coatings would reduce
systemic absorption through this path aswell.
However, if the coating does turn out to
be effective, Peden envisions other pharma-
ceutical uses for it, such as in delivery systems
for inhaled antibiotics and for human
immunodeficiency virus treatments. The
researchers are also looking at uses outside the
pharmaceutics industry. Singh says that man-
ufacturers of flat panel displays have shown
interest in the process for coating phosphorus
particles, forexample.
As for asthma treatments, Hochhaus cau-
tions that this application is still in earlydevel-
opment. Patent applications were filed only
recently, and clinical trials are still 5-6 years
away, he says. Says Zeldin, "It's a novel
approach, but it remains to be seen whether it
will turn out to be important."
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